Maternal blood screening for Down's Syndrome, Edward's Syndrome and Neural Tube Defect
The most flexible Down's syndrome screening program
Prenatal diagnostic of Down’s Syndrome and other chromosomal abnormalities is based on foetal karyotyping. Because of costs and risks associated with amniocentesis, karyotyping is restricted to patients at increased risk.
The age of the mother, her biochemical markers and ultrasound findings are useful criteria for antenatal screening. They are used alone or more often in combination. Choosing markers for multiple parameters screening allows for a valid and empirically established statistical methodology.
ZenTech proposes a complete program for antenatal screening, including Elisa kits and a software especially devised for evaluating the risk of Down's Syndrome (Trisomy 21), Edward’s Syndrome (Trisomy 18) and Neural Tube Defect (NTDs) during the first and second trimester of pregnancy.